CMMB - CIK 0001534248
Chemomab Therapeutics Ltd. (CMMB) reported net income of -$8.99M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$8.99M | +35.5% |
| FY 2024 | -$13.95M | +42.4% |
| FY 2023 | -$24.22M | +12.4% |
| FY 2022 | -$27.65M | -121.6% |
| FY 2021 | -$12.48M | -109.7% |
| FY 2020 | -$5.95M | +78.1% |
| FY 2019 | -$27.12M | -96.6% |
| FY 2018 | -$13.80M | - |
Chemomab Therapeutics Ltd. (CMMB) reported net income of -$8.99M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2018 and fiscal 2025, Chemomab Therapeutics Ltd.'s net income grew from -$13.80M to -$8.99M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.